Cleveland BioLabs (CBLI), BARDA Conclude Advanced CBLB502 Funding Talks
Tweet
Share
E-mailGet Alerts CBLI Hot Sheet
Join SI Premium – FREE
Cleveland BioLabs, Inc. (Nasdaq: CBLI) and the Biomedical Advanced Research and Development Authority of the Department of Health and Human Services (BARDA) have recently concluded advanced stages of contract negotiations for funding of certain CBLB502 development activities included in the Company's 2010 Proposal to BARDA.
Further talks will depend on clarification of the development path for CBLB502 with the U.S. Food and Drug Administration. BARDA has indicated that the Company may resubmit an updated proposal upon confirmation from the FDA there are no objections to the Company proceeding with its development plan as a result of this review.
Further talks will depend on clarification of the development path for CBLB502 with the U.S. Food and Drug Administration. BARDA has indicated that the Company may resubmit an updated proposal upon confirmation from the FDA there are no objections to the Company proceeding with its development plan as a result of this review.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Getty Realty discloses separation terms for departing accounting officer
- Veeva Systems names Dan Rizzo EVP of sales amid leadership change
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
